PTGX Protagonist Therapeutics, Inc.

0  -1%
Previous Close 10.56
Open 10.61
Price To book 2.02
Market Cap 174.92M
Shares 16,787,000
Volume 10,955
Short Ratio 5.42
Av. Daily Volume 31,887

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b initiation announced January 17, 2017. Interim futility analysis 2H 2017.
Ulcerative colitis

Latest News

  1. Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week
  2. Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference
  3. Protagonist Therapeutics posts 4Q loss
  4. Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
  5. Protagonist Therapeutics to Present at the Barclays Global Healthcare Conference
  6. Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidates at European Crohn's and Colitis Organization (ECCO) Congress
  7. Protagonist Therapeutics to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
  8. Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
  9. Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100
  10. Here are the Bay Area's IPO winners and losers for 2016
  11. How Corenergy Infrastructure Trust Inc (CORR) Stacks Up Against Its Peers
  12. Protagonist Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update
  13. Supersized IPO charges up S.F. med device maker's first day
  14. Latest Bay Area IPO stock jumps after upsized offering raises $107M
  15. Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna
  16. Protagonist Therapeutics Inc (PTGX): RA Capital Management Acquires 6.8% Stake
  17. Protagonist Therapeutics Inc (PTGX): Adage Capital Management Reveals 9.69% Stake